And the really great thing is that the Supreme Court doesn’t have to fully rule in Amarin’s favor. All it has to do is return it to Judge Du with instructions to weigh the secondary factors differently. That, in effect, negates Judge Du’s earlier decision. No way anybody waits for a new ruling. Amarin gets to negotiate a settlement from a position of strength. Everybody saves face. The Federal Circuit never sees the case again. Hikma, realizing the folly of the “skinny label,” gets to escape its promise to shareholders to market an unprofitable generic Vascepa right away. And JT gets to brag that he knew he was right all along.
News 
Market Data 
Discover 
